Blincyto Blinatumomab 35 Mcg

Blinatumomab, sold under the brand name Blincyto, is a biopharmaceutical medication used as a second-line treatment for Philadelphia chromosome-negative relapsed or refractory acute lymphoblastic leukemia. It belongs to a class of constructed monoclonal antibodies, bi-specific T-cell engagers, that exert action selectively and direct the human immune system to act against tumor cells. Blinatumomab specifically targets the CD19 antigen present on B cells. In December 2014, it was approved by the US Food and Drug Administration under the accelerated

Specification/Additional Details

• Packaging Size – 1mlx12.5 mcg
• Brand – BLiNCYTO
• Prescription/Non prescription
• Form – Injection
• Generic Name – Blinatumomab